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Abstract 
Introduction The mental health prognosis following a venous thromboembolism in youth has not 
been investigated comprehensively. Using psychotropic drug purchase as a proxy for mental health 
status, we investigated this issue in a large cohort of young incident venous thromboembolism 
patients. 
 
Methods Using Danish nationwide administrative registries from the period 1997-2010, we 
identified 4,132 patients aged 13-33 years with a first-time venous thromboembolism diagnosis and 
no history of psychotropic drug usage. We sampled comparison cohort of random general 
population controls, matched individually in a 1:5 ratio based on sex and birth year. Participants 
were followed in prescription purchase registries for their first psychotropic drug purchase.  
 
Results Among young venous thromboembolism case cases, the 1-year risk of psychotropic drug 
purchase was 7.1% (95% confidence interval [CI] 6.3, 7.9) and the 5-year risk 22.1% (95% CI 20.7, 
23.5). This was substantially higher than among population controls, with 1- and 5-year risk 
differences relative to the controls of 4.7% (95% CI 3.9, 5.5), and 10.8% (95% CI 9.4, 12.3), 
respectively. Adjustment for the effects of recent pregnancy or somatic provocations attenuated risk 
differences to 4.1% (95% CI 3.5, 5.1) after 1 year and 9.6% (95% CI 8.3, 11.2) after 5 years.  
 
Conclusions A venous thromboembolism diagnosis in youth is associated with a poorer mental 
health prognosis: one in five patients are prescribed psychotropic medication within the first 5 year 
after diagnosis.  
 
Key words: Adolescent: Anxiety Disorders: Depression: Psychotropic Drugs: Venous 
Thromboembolism: Young Adults  
 
Abbreviations CI=confidence interval; QOL= quality of life 
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Introduction  
Chronic medical illness in youth can lead to emotional and behavioural problems and is a risk factor 
for poor mental health, including psychiatric disorders [1]. Venous thromboembolism, a common 
and potentially life-threatening disease encompassing deep venous thrombosis and pulmonary 
embolism, has received limited attention in this setting, perhaps because of its lower incidence in 
the younger populations (1-2 per 10.000 person years) [2,3]. Nonetheless, recent evidence suggests 
that the incidence of venous thromboembolism in adolescents and young adults is increasing [3,4]. 
It has been argued that venous thromboembolism should generally be considered a chronic illness, 
owing to its long-term somatic consequences which include post thrombotic syndrome, chronic 
pulmonary hypertension, and a risk of recurrent venous thromboembolism [5,6]. These long-term 
consequences have also been reported in young populations [7,8], but it is unclear whether venous 
thromboembolism in a young population should be considered a chronic illness in terms of its 
association with mental health. One study reported young venous thromboembolism patients to 
have lower self-esteem, and higher impairment in social activities as well as in familial functioning 
[9]. Other research on this issue pertains to elderly populations, in which venous thromboembolism 
has been found to be associated with poorer mental quality of life [10,11]. One study [12] examined 
anxiety and depression following venous thromboembolism, reporting elevated levels of anxiety 
and depression symptoms in the first 1-4 weeks following the event. In patients with chronic 
cardiovascular disease, anxiety is reported to persist in 20-25 % of patients following an acute 
cardiac event [13], and especially younger cardiac patients experience impaired mental health [14].   
 
The purpose of the present study was to use epidemiological methods to describe the mental health 
prognosis following a venous thromboembolism diagnosis in youth. To quantify mental health 
status, we used psychotropic drug purchase derived from prescription purchase registries as a proxy 
measure. We hypothesized that young patients with venous thromboembolism would have a higher 
risk of psychotropic drug purchase compared to population controls.   
 
Methods 
Study design 
We used the unique civil registration number assigned to all Danish residents to link data from four 
nationwide registries [15]: (i) Danish Civil Registration System recording gender, date of birth, 
death, and emigration of all Danish residents [16]; (ii) The Danish National Patient Register which 
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contains detailed information on more than 99% of all somatic hospital admissions [17]; (iii) The 
Danish National Prescription Registry which contains ATC codes and package sizes for all 
prescription purchases in Denmark since 1995 [18]; (iv) The Danish Medical Birth Registry which 
has registered all births in Denmark since 1973 [19]. 
 
In the registries, we identified all incident cases of venous thromboembolism among 13-33 year old 
Danish residents in the period January 1, 1997, to March 1, 2010. A diagnosis of venous 
thromboembolism was classified according to the Danish version of the International Classification 
of Diseases (ICD) 8
th
 and 10
th
 revision (ICD-8, ICD-10), presented in the supplementary Table 1. 
The index date was defined as the date of a venous thromboembolism diagnosis. Using a risk-set 
sampling approach, we randomly sampled from the full Danish population five venous 
thromboembolism-free population controls per case, matching on sex and birth year. The index date 
of each control was set to the index date of their corresponding case.  
 
Transient risk factors for venous thromboembolism of potential importance to mental health 
prognosis were also ascertained. We defined „recent provocation‟ as any of the following: a 
diagnosis of cancer (ICD-10, neoplasm‟s C00-D48) or autoimmune disease (ICD-10 rheumatoid 
arthritis M05-M07, inflammatory bowel disease K50-K51) within 1 year of index date; trauma 
requiring hospital admission within 3 months of index date; surgery requiring one or more days of 
hospital admission within the last 3 months of index date. In the Danish Medical Birth Registry, we 
identified „recent pregnancy‟ as childbirth at up to 8 weeks before and up to 42 weeks after the 
index date. Cases with an ICD-8 or ICD-10 code indicating pregnancy-related venous 
thromboembolism (see Supplementary Table 1) were also classified as „recent pregnancy‟. 
 
In the Danish National Prescription Registry, we identified prescription purchases using the 
Anatomical Therapeutic Chemical Classification System (ATC) in the period 1 January 1995 to 31 
December 2011 for the following psychotropic drug purchase: antipsychotics (ATC codes: N05A); 
anxiolytics (ATC codes: N05B); sedatives (ATC codes: N05CD, N05CF, R06AD); and 
antidepressives (ATC codes: N06A) (supplementary table 2).  
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The final case and control cohorts were defined by excluding both cases and corresponding controls 
for all cases who had purchased psychotropic drugs within 2 years of the index date; and remaining 
controls with a history of a psychotropic drug purchase within 2 years of the index date. 
 
Statistical analysis 
Descriptive data were presented as counts and percentages. Time to first psychotropic drug 
purchase was measured from the index date. Subjects were right-censored at the time of death, 
emigration, or 31 December 2011, whichever came first. The cumulative risk of purchase of any 
psychotropic drug according to case status as a function of time was quantified using a Kaplan-
Meier plot. We used pseudo-value regression [20] on a risk difference scale to assess the association 
between the case status and the risk of a psychotropic drug purchase event within 1 year, 
respectively 5 years. The pseudo-value regression technique reduces to regression on the event 
status indicator when there is no censoring and accounts for censored observations before 1 year, 
respectively 5 years. To ensure that risk differences were assessed between comparable venous 
thromboembolism cases and population controls, we also considered multivariate regression of 
pseudovalues, adjusting for the effect of „recent pregnancy‟ (binary) and „recent provocation‟ 
(binary). We repeated regression analyses after stratifying analyses on sex, venous 
thromboembolism type (pulmonary embolism or deep vein thrombosis), and calendar period (index 
date 1997-2002 or 2003-2010). We also carried out analyses for each psychotropic drug endpoint 
(antipsychotics; anxiolytics; sedatives; antidepressives) separately. Stata/MP version 12.1 was used 
for statistical analysis. 
 
Results  
Study population characteristics 
We identified a total of 5,027 patients aged 13-33 years with an incident venous thromboembolism 
diagnosis. After exclusion of cases who died on the day of diagnosis (n = 14) and cases who had a 
psychotropic drug prescription purchases within 2 years before the index date (n = 881), 4,132 cases 
constituted the venous thromboembolism cohort. Of these 20.6% (n = 852) were pulmonary 
embolisms. Among the population controls, 1,368 had purchased psychotropic drugs within 2 years 
of the index date and were excluded, leaving 19,292 subjects in the control cohort. Baseline 
characteristics are shown in Table 1.  
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In the venous thromboembolism cohort, almost 75% were women and the median age was 25 years. 
Older age groups were more strongly represented, with the 28-33 year-old group 5 times larger than 
the 13-18 year-old group. The number of women with a recent pregnancy was 7% higher in the 
venous thromboembolism cohort compared to the control cohort; also, the proportion of patients 
who had experienced a recent provocation was 10-fold higher in the venous thromboembolism 
cohort compared to the control cohort.  
 
Venous thromboembolism and psychotropic drug purchase 
The Kaplan-Meier estimates of cumulative risk showed a substantially higher overall risk of any 
psychotropic drug purchases in the venous thromboembolism cohort compared to the control cohort 
(Figure 1). The absolute risks and risk differences of psychotropic drug purchases according to 
venous thromboembolism status are presented in Table 2. In the venous thromboembolism cohort, 
the 1-year risk of psychotropic drug purchase was 7.1% (95% confidence interval (CI): 6.3, 7.9) and 
the 5-year risk 22.1% (95% CI: 20.7, 23.5), corresponding to 1- and 5-year risk differences relative 
to the control cohort of 4.7% (95% CI: 3.9,5.5), and 10.8% (95% CI: 9.4,12.3), respectively. Risk 
differences for the venous thromboembolism cohort relative to the control cohort as a function of 
time is presented in Figure 2. The higher risk of psychotropic drug purchase in the venous 
thromboembolism cohort persisted when adjusting for the effect of recent pregnancy or recent 
provocation, (1-year risk difference 4.1% (95% CI: 3.5,5.1), 5 year risk difference 9.6% (95% CI: 
8.3,11.2).  
 
In the analyses stratified by various baseline characteristics, a substantial risk differences between 
venous thromboembolism cases and controls persisted across age strata (age≤ 25 years and age > 25 
years) and period of index date (1997-2002 and 2003-2010, respectively), as well as among both 
female and males (table 2). Of note, the 5-year risk difference was higher for males compared to 
females. Also, the 1-year risk difference was increased among PE patients compared to DVT 
patients. 
 
We found no marked difference in the distribution of the psychotropic drug classes purchased in the 
venous thromboembolism cohort and the control cohort. Antidepressants were the most frequently 
purchased drug (53% of all purchases) followed by anxiolytics (20%), sedatives (22%), and finally 
antipsychotics (5%). To investigate the robustness of our findings when more specific endpoints 
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were used, we defined four different composite endpoints given purchase within each of the drug 
classes, antipsychotics, anxiolytics, sedatives, antidepressives. Repeating the main analyses for 
these endpoints did not change the overall findings (Supplementary table 3-6).  
 
Discussion 
In this large-scale registry-based study, we found that young patients diagnosed with venous 
thromboembolism in Denmark during the period 1997-2011 had a substantially higher risk of 
psychotropic drug use compared to age- and sex-matched population controls. The increased risk 
persisted after adjustment for known risk factors of venous thromboembolism, including cancer, 
trauma, surgery, inflammatory bowel disease, rheumatoid arthritis and pregnancy.  
 
Our finding of an association between a venous thromboembolism diagnosis and long-term 
increased risk of psychotropic drug purchase is in line with observations in young chronically ill 
patients where psychiatric symptoms develop and persist over time, and result in a higher adjusted 
lifetime prevalence of psychiatric disorders [1]. Whether the present association derives from the 
same attributes is unclear. However, it has been argued that venous thromboembolism has the 
characteristics of a chronic illness, owing to the high risk of recurrence (10-year risk of 30%) and 
the potential for long-term somatic consequences; including post thrombotic syndrome, pulmonary 
hypertension, and the need for lifelong medicinal treatment [5,6].  
 
We emphasize that our findings are strictly associational and do not imply that venous 
thromboembolism is a direct cause of decreased mental health. For example, although we adjusted 
for transient risk factors, it cannot be ruled out that the same inciting event (e.g. immobility) caused 
both the VTE and triggered mood disorder; or that the incident VTE may have necessitated more 
access to care, thereby leading to revealing of a previously undiagnosed psychiatric illness.  
However, the acute, life-threatening nature of venous thromboembolism is also a viable explanation 
of the increased risk of psychotropic drug purchase. Acute life-threatening medical events have 
been reported to negatively impact mental health of children and adolescents [20]. We observed 
similarly increased risks when comparing both patients with deep venous thrombosis and the more 
serious condition of pulmonary embolism to population controls. This is in line with the findings of 
Lukas and colleagues, who found no difference in mental health-related quality of life (QOL) 
among patients with deep venous thrombosis and pulmonary embolism [21]. Indeed, our finding is 
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consistent with the assertion that, when it comes to determining vulnerability to psychiatric 
disorders in young patients, the retrospective appraisal by the patient of how threatening the disease 
is plays a more prominent role than the actual life threat [1].  
 
Socioeconomic factors were unavailable in the present study, but low socioeconomic position is 
generally associated with higher psychiatric morbidity, and has previously been associated with 
low-QOL scores in patients with pregnancy-related deep venous thrombosis [22]. Our findings 
encourage further exploration of these and other risk factors for mental health problems following 
venous thromboembolism in youth.      
 
Limitations  
The main strength of our study was the large number of venous thromboembolism patients included 
and the minimal loss to follow-up. The use of nationwide administrative registry data allowed a 
large-scale population-based design with complete long-term follow-up on psychotropic drug 
purchases, as well as death and migration. The use of administrative registries also entails some 
limitations. For example, misclassification of both venous thromboembolism diagnosis and baseline 
comorbidities cannot be ruled out. Validation studies in Denmark have found a positive predictive 
value of venous thromboembolism diagnosis of 75%, both in general [23] and in age specific 
analysis of adolescents [24]. In addition, the reliance on prescription purchase registries to define 
comedication at baseline has some limitations, since patients may not take their prescription 
medications. Another limitation relates to the use of psychotropic drug purchase as a proxy for 
mental health. Venous thromboembolism patients may be more likely to receive a psychotropic 
drug prescription simply because of frequent contact with the health care system. Lastly, the present 
study is insufficient to establish a causal link between venous thromboembolism and decreased 
mental health. Further research is needed to explore the nature and etiological reasons of the 
association. 
 
 Conclusions 
Venous thromboembolism among adolescents and young adults has the characteristics of a chronic 
illness in relation to mental health: within the first 5 year after diagnosis, one in five young venous 
thromboembolism patients will experience mental health issues requiring psychotropic medication. 
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A long-term follow-up by the primary care physician or an outpatient clinic, with a focus on mental 
health, may be necessary in this young age group.  
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Table 1. Baseline characteristics for the venous thromboembolism cohort and the control cohort 
Variable Case cohort Control cohort1 
Females, n (%) 2,905 (70.3) 13,472 (69.8) 
     Recent pregnancy2 725 (17.5) 2,237 (11.6) 
Age at index date   
     13-18 313 (7.6) 1,539 (8.0) 
     18-23 861 (20.8) 4,140 (21.5) 
     23-38 1,251 (30.3) 5,801 (30.1) 
     28-33 1,707 (41.3) 7,812 (40.5) 
Period of index date    
    1997-2002 1,672 (40.5) 7,906 (41.1) 
    2003-2010 2,460 (59.5) 11,386 (59.0) 
Recent provocation3  684 (16.5) 311 (1.6) 
    Cancer 68 (1.7) 18 (0.1) 
    Surgery 548 (13.3) 251(1.3) 
    Trauma 172 (4.2) 26 (0.1) 
    Inflammatory bowel disease 55(1.3) 26(0.13) 
    Rheumatoid arthritis   9(0.2) 6(0.03) 
1 Population controls matched on sex and birth year. 
2 Childbirth at up to 8 weeks before and up to 42 weeks after the index date or cases with ICD-8 or ICD-10 code 
indicating pregnancy-related VTE. 
3 Diagnosis of cancer, rheumatoid arthritis, inflammatory bowel disease within 1 year of index date; trauma requiring 
hospital admission within 3 months of index date; surgery requiring one or more days of hospital admission within the 
last 3 months of index date. 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
13 
 
Table 2: Risks and risk differences of any psychotropic drug purchase for venous 
thromboembolism cases and controls.  
  Risk of psychotropic drug 
purchase (per cent) 
Risk difference: cases 
vs. controls (95% CI) 
Adjusted risk 
difference3: cases vs. 
controls (95% CI)  Cases1  Controls2  
Within 1 year  
after index date 
    
All 7.1 2.4 4.7 (3.9,5.5) 4.1 (3.3,4.9) 
     
Male 7.1 1.9 5.2 (3.7,6.7) 4.7 (3.2,6.3) 
Female 7.1 2.6 4.5 (3.5,5.5) 3.9 (2.9,4.9) 
Age ≤ 25 years 6.4 1.9 4.5 (3.2,5.7) 3.7 (2.4,5.0) 
Age > 25 years  7.6 2.7 4.9  (3.8,5.9) 4.4 (3.3,5.5) 
Index date 1997-2002 6.8 2.3 4.5 (3.2,5.7) 3.9 (2.7,5.2) 
Index date 2003-2010 7.4 2.5 4.9 (3.8,5.9) 4.2 (3.1,5.3) 
Deep venous thrombosis 6.8 2.3 4.5 (3.6,5.4) 4.0 (3.1,5.0) 
Pulmonary embolism 8.5 2.8 5.7 (3.7,7.6) 5.2 (3.3,7.2) 
     
Within 5 years  
after index date 
    
All 22.1 11.3 10.8 (9.4,12.3) 9.6 (8.1,11.1) 
     
Male 22.2 8.5 13.7 (11.1,16.3) 11.7 (9.0,14.3) 
Female 22.1 12.5 9.6 (7.8,11.3) 8.7 (6.9,10.5) 
Age ≤ 25 years 21.2 10.2 11.0 (8.7,13.2) 9.7 (7.4,12.1) 
Age > 25 years  22.7 12.0 10.7 (8.8,12.6) 9.6 (7.7,11.5) 
Index date 1997-2002 20.6 11.4 9.1 (6.8,11.5) 7.7 (5.3,10.1) 
Index date 2003-2010 23.1 11.2 12.0 (10.1,13.8) 10.9 (9.0,12.8) 
Deep venous thrombosis 21.9 11.1 10.8 (9.2,12.5) 9.8(8.2,11.5) 
Pulmonary embolism  22.9 12.2 10.7 (7.5,13.9) 9.4 (6.1,12.7) 
1 First time incident VTE cases among 13-33 year old Danish residents.  
2 Population controls matched on sex and birth year.  
3 Adjusted for diagnosis of cancer, rheumatoid arthritis, inflammatory bowel disease within 1 year of index date; 
trauma requiring hospital admission within 3 months of index date; surgery requiring one or more days of hospital 
admission within the last 3 months of index date and childbirth at up to 8 weeks before and up to 42 weeks after the 
index date. 
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Figure legends  
Figure 1. Kaplan-Meier estimates of the risk of any psychotropic drug purchase as a function of 
time, according to venous thromboembolism case status   
Figure 2. Risk differences of any psychotropic drug purchase for venous thromboembolism-cases 
vs. population controls as a function of time  
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Figure 1 
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Figure 2 
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HIGHLIGHTS  
 
* VTE in the young is associated with a poor mental health prognosis 
* 1 in 5 patients purchase psychotropic drugs within 5 years after VTE diagnosis 
* Among similarly aged peers, only 1 in 10 purchase psychotropics in the same period 
* Young VTE patients may need long-term followup with a focus on mental health 
